The decision comes amid a shortage

Jun 12, 2026

12:42 pm

What's the storyIndia's National Pharmaceutical Pricing Authority (NPPA) has approved a 50% price hike for two critical anti-cancer drugs - carboplatin and cisplatin.

The NPPA had received numerous requests from pharmaceutical companies seeking upward revision of prices due to substantial increase in Active Pharmaceutical Ingredient (API) prices, escalation in production costs, and fluctuations in foreign exchange rates.